A fantastic first year – Swizzard Pharma’s highlights
Swizzard is proud to have achieved some major milestones during 2021 – our year of foundation. In this review, we share some highlights from our projects and company development one year in.
We supported a company in bringing a medical breakthrough to Swiss patients, which will help improve quality of life for affected patient groups. We also supported two companies as they worked to set up a fully operational Swiss affiliate, sharing our experience and understanding of the Swiss market to smooth and streamline the process. Five biotech/pharma companies engaged Swizzard to drive strategy development and launch readiness in Switzerland. We also established the business case for a rare disease indication, developed the go-to-market strategy for a gene therapy player and engaged in patient finding within the ultra-rare disease environment. Finally, Swizzard implemented an early access framework and outlined the market access and negotiation strategy.
Company development The Swizzard brand is now safely protected and registered with the Swiss Federal Institute of Intellectual Property. Bruno Zimmermann and Jonas Mülchi joined Swizzard’s Board of Directors and are supporting CEO Michael Zürcher with their extensive knowledge and experience. Our first year also saw the launch of the Swizzard Corporate Competence Center, where four ambitious team members share their complementary skill sets to address key questions around Swiss market entry, support go-to-market strategies and enable custom-built projects. Swizzard enjoys a growing social media reach, with more than 750 followers on LinkedIn who benefit from our regular insights, tips and tricks.
The Swiss biotech/pharma market is stronger than ever and forward-thinking companies are in a leading position to bring innovation to Swiss patients. We look forward to exciting new tasks and serving our customers with passion, commitment and dedication in 2022.